The World Health Organization (WHO) has granted an emergency use listing (EUL) to Serum Institute of India Pvt. Ltd.’s version of NVX-CoV2373, Novavax, Inc.'s recombinant nanoparticle protein-based COVID-19 vaccine, for immunization of individuals 18 years of age and older.
Coronavirus Update: Novavax Vaccine Listed By WHO, Filed In Japan
Plus, Booster OK For Moderna In Japan
The WHO has granted an emergency listing to Novavax's COVID-19 vaccine, paving the way for wider use along with a new approval in the EU this week. The protein-based product has also just been filed in Japan, where Moderna's mRNA shot has been newly cleared for booster use.
More from COVID-19
More from Scrip
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.